Publication date: Jul 10, 2026
Objectives: Coronavirus disease 2019 (COVID-19) poses a significant threat to kidney transplant recipients (KTRs) due to chronic immunosuppression. While Azvudine has demonstrated antiviral efficacy, its long-term impact on allograft function in KTRs remains unknown. This single-arm retrospective study provides a comprehensive evaluation of the outcomes. Methods: This single-center, retrospective study consecutively enrolled 20 KTRs diagnosed with COVID-19 during the Omicron surge (December 2022-January 2023), all treated with an Azvudine-centered regimen. Clinical data, treatment responses, and serial renal function parameters were analyzed. Long-term follow-up extended to a median of 39 months. Results: The median time to COVID-19 nucleic acid negativity was 13. 22 days. Renal function improved significantly during treatment: estimated glomerular filtration rate increased by a mean of 27. 29 mL/min/1. 73 m, and serum creatinine decreased by 57. 72 umol/L (both p
| Concepts | Keywords |
|---|---|
| Coronavirus | Azvudine |
| December | COVID-19 |
| Kidney | immunosuppression |
| Therapy | kidney transplantation |
| long-term outcomes | |
| renal function |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | COVID-19 |
| drug | DRUGBANK | Creatinine |
| disease | MESH | included |
| disease | MESH | co-infections |